Navigation Links
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
Date:5/20/2013

CHAPEL HILL, N.C., May 20, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin versus levofloxacin in Cempra's prior Phase 2 clinical trial in outpatients with community acquired bacterial pneumonia (CABP). Solithromycin's efficacy profile was comparable to levofloxacin's while solithromycin demonstrated favorable tolerability versus levofloxacin. Solithromycin also demonstrated an enhanced anti-inflammatory response in in vitro studies based on decreased production of inflammatory cytokines and showed re-sensitization to steroids.  The Study, Jamieson et al. (Poster Board # H55) was presented at 8:15 a.m. to 4:30 p.m. EDT, Sunday, May 19.

"Macrolides, such as azithromycin, have been shown to reduce morbidity and mortality in chronic lung diseases such as COPD and diffuse panbronchiolitis," said Prabhavathi Fernandes , Ph.D., president and chief executive officer of Cempra. "The results from this analysis of our Phase 2 clinical trial of oral solithromycin in CABP patients suggest that the comparable early clinical response rates of solithromycin versus levofloxacin may be enhanced by anti-inflammatory properties. Our data provide additional support for our development of solithromycin as a differentiated drug-resistant treatment for CABP and with potential for use in COPD."

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra'
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
2. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
3. Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
4. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
5. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
6. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
7. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
8. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
9. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
10. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
11. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that it will ... open on Tuesday, April 28, 2015. United ... 28, 2015, at 9:00 a.m. Eastern Time.  The teleconference ... 1-970-315-0533.  A rebroadcast of the teleconference will be available ...
(Date:4/21/2015)... Thornton Cleveleys (UK) (PRWEB) April 21, 2015 ... PEEK* technology and its clinical applications will ... Meeting. Participants include engineers, scientists, regulators and ... worldwide. The meeting is sponsored by Invibio ... PEEK polymer-based biomaterials, a specialist in manufacturing ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Whether it’s ... a lab, or bolted to a Kessler CineDrive ... or at the beach, the TS3-H is designed to help ... on a brand-new state-of-the-art 5MP sensor, the TS5-H offers the ... with superior imaging characteristics. , According to Tom Boldt ...
(Date:4/20/2015)... -- Stent retriever thrombectomy, an endovascular technique that ... reduced disability after stroke, according to a groundbreaking ... the Society of Vascular and Interventional Neurology (SVIN).  ... forward that will change the way we approach ... who is associate professor of Neurology and Neurosurgery ...
Breaking Biology Technology:2nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3
... will potentially enable access to MRI exams for ... implantable cardiac ... Boston,Scientific Corporation (NYSE: BSX ) and Surgi-Vision, ... development arrangement for,magnetic resonance imaging (MRI)-safe technology. Physician implanters ...
... ... 2008, FT. MYERS, Fla., April 15 ... the,Securities and Exchange Commission its annual report on Form 10-KSB for the,year ended ... http://www.SEC.gov ., The audited financial statements for the year ended December ...
... April 15 Arpida Ltd.,(SWX: ARPN) today announced ... Thursday,17 April 2008 at 8.30am CET. In this ... need and developments in the area of anti-infective,drugs ... meeting of the Anti-Infective,Drugs Advisory Committee. During that ...
Cached Biology Technology:Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 2Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 3NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Patients who have high blood sugar before undergoing ... clots, deep vein thrombosis and even pulmonary embolism ... of anesthesiology in the Artificial Pancreas Center at ... Philadelphia, and his colleagues examined records of nearly ...
... protect against some food allergies. Kefir, a traditional fermented drink, ... is often used to wean babies, as it is easily ... the age of three, with around 5-8% of infants at ... food. , "Friendly" bacteria in kefir may play a role ...
... in the event of a large-scale smallpox bioterrorist attack ... by researchers at Fred Hutchinson Cancer Research Center that ... , Instead, the current U.S. government policy of post-release ... workers and close contacts would be sufficient to thwart ...
Cached Biology News:Jefferson scientists find high glucose before surgery raises risk of dangerous complications 2Friendly bacteria in alcoholic milkshake could fight food allergies 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
...
...
Biology Products: